TikkunLev Therapeutics
TikkunLev Therapeutics is dedicated to revolutionizing the treatment of heart failure by targeting the underlying biology of failing heart muscle. The company develops first-in-class precision therapies, with a focus on repairing failing heart muscle to reverse heart failure. Their lead program, TLT-101, is in IND-enabling development for non-ischemic dilated cardiomyopathy (DCM), aiming to deliver a potential breakthrough in cardiovascular medicine.
Industries
Nr. of Employees
small (1-50)
Products
Lead precision gene therapy program (IND-enabling) for non-ischemic dilated cardiomyopathy
A lead precision gene therapy program designed to repair failing heart muscle and reverse remodeling in non-ischemic dilated cardiomyopathy; demonstrated durable efficacy and favorable safety in multiple preclinical studies including large-animal models and being advanced through IND-enabling development.
Lead precision gene therapy program (IND-enabling) for non-ischemic dilated cardiomyopathy
A lead precision gene therapy program designed to repair failing heart muscle and reverse remodeling in non-ischemic dilated cardiomyopathy; demonstrated durable efficacy and favorable safety in multiple preclinical studies including large-animal models and being advanced through IND-enabling development.
Services
End-to-end IND-enabling program activities including preclinical study coordination, regulatory strategy, and preparation for IND submission.
Collaborative conduct of translational efficacy and safety studies using established large-animal disease models and on-site operating room facilities at an academic partner to support therapeutic development.
End-to-end IND-enabling program activities including preclinical study coordination, regulatory strategy, and preparation for IND submission.
Collaborative conduct of translational efficacy and safety studies using established large-animal disease models and on-site operating room facilities at an academic partner to support therapeutic development.
Expertise Areas
- Gene therapy development
- Translational cardiology and heart failure therapeutics
- Preclinical large-animal model studies
- Biomarker development and validation (blood-based)
Key Technologies
- Systemic intravenous gene delivery
- Viral and non-viral gene delivery methods
- Blood-based biomarker assays
- Large-animal preclinical models (minipig)
News & Updates
Our latest preclinical study, published in Nature Regenerative Medicine, was recently featured in The Telegraph. The study demonstrates the potential of gene therapy to cure heart failure in pigs.
The study, conducted by Dr. Robin Shaw and his team, demonstrates the efficacy of cBIN1 therapy in recovering heart function and reversing remodeling in large animal models of severe non-ischemic dilated cardiomyopathy (DCM).
The company announced its launch, its lead program for non-ischemic DCM, seed financing, and the establishment of its Scientific Advisory Board. The company is developing therapies targeting the causal disease biology of failing heart muscle.
TikkunLev aims to revolutionize heart failure treatment by repairing failing heart muscle. Their approach involves targeting the underlying biology of the disease, with a focus on their lead program TLT-101, which is in IND-enabling development.
The company has published significant research demonstrating the potential of cBIN1 gene therapy to repair heart muscle and reverse heart failure in preclinical models.
Our latest preclinical study, published in Nature Regenerative Medicine, was recently featured in The Telegraph. The study demonstrates the potential of gene therapy to cure heart failure in pigs.
The study, conducted by Dr. Robin Shaw and his team, demonstrates the efficacy of cBIN1 therapy in recovering heart function and reversing remodeling in large animal models of severe non-ischemic dilated cardiomyopathy (DCM).
The company announced its launch, its lead program for non-ischemic DCM, seed financing, and the establishment of its Scientific Advisory Board. The company is developing therapies targeting the causal disease biology of failing heart muscle.
TikkunLev aims to revolutionize heart failure treatment by repairing failing heart muscle. Their approach involves targeting the underlying biology of the disease, with a focus on their lead program TLT-101, which is in IND-enabling development.
The company has published significant research demonstrating the potential of cBIN1 gene therapy to repair heart muscle and reverse heart failure in preclinical models.